AS

ASKA Pharmaceutical Holdings CO., Ltd.

Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.

4886 | T

Overview

Corporate Details

ISIN(s):
JP3119660003
LEI:
Country:
Japan
Address:
港区芝浦二丁目5番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ASKA Pharmaceutical Holdings Co., Ltd. is the holding company for the ASKA Pharmaceutical Group, established in April 2021. The group's core business encompasses the research, development, manufacturing, and sale of pharmaceuticals. Leveraging its long-standing expertise in hormone-related technologies, the company focuses on developing innovative and original medicines, with a particular strength in therapeutic areas such as internal medicine, obstetrics and gynecology, and urology. The group's operations also extend to the animal health and hormone testing businesses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 07:10
Registration Form
確認書
Japanese 8.2 KB
2025-11-07 07:09
Interim Report
半期報告書-第5期(2025/04/01-2026/03/31)
Japanese 195.0 KB
2025-06-27 08:15
Post-Annual General Meeting Information
臨時報告書
Japanese 31.4 KB
2025-06-20 08:11
Registration Form
確認書
Japanese 8.2 KB
2025-06-20 08:10
Governance Information
内部統制報告書-第4期(2024/04/01-2025/03/31)
Japanese 28.7 KB
2025-06-20 08:08
Annual Report
有価証券報告書-第4期(2024/04/01-2025/03/31)
Japanese 1.4 MB
2025-02-07 07:41
Foreign Filer Report
臨時報告書
Japanese 21.4 KB
2024-11-08 07:04
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-08 07:02
Interim Report
半期報告書-第4期(2024/04/01-2025/03/31)
Japanese 183.3 KB
2024-06-28 07:12
Post-Annual General Meeting Information
臨時報告書
Japanese 22.0 KB
2024-06-25 06:40
Registration Form
確認書
Japanese 8.2 KB
2024-06-25 06:39
Governance Information
内部統制報告書-第3期(2023/04/01-2024/03/31)
Japanese 23.6 KB
2024-06-25 06:37
Annual Report
有価証券報告書-第3期(2023/04/01-2024/03/31)
Japanese 1.3 MB
2024-02-09 07:07
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-02-09 07:05
Quarterly Report
四半期報告書-第3期第3四半期(2023/10/01-2023/12/31)
Japanese 155.2 KB

Automate Your Workflow. Get a real-time feed of all ASKA Pharmaceutical Holdings CO., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ASKA Pharmaceutical Holdings CO., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ASKA Pharmaceutical Holdings CO., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Kairos Pharma, LTD. Logo
Develops novel oncology therapies to reverse drug resistance and immune suppression.
United States of America
KAPA
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA
KAMADA LTD Logo
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America
KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom
KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden
KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea
217730

Talk to a Data Expert

Have a question? We'll get back to you promptly.